Clinical evaluation of super-responders vs. non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1129-2377
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Clinical evaluation of super-responders vs. non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience ; volume:24 ; number:1 ; day:27 ; month:2 ; year:2023 ; pages:1-10 ; date:12.2023
The journal of headache and pain ; 24, Heft 1 (27.2.2023), 1-10, 12.2023
- Creator
-
Raffaelli, Bianca
Fitzek, Mira
Overeem, Lucas H.
Storch, Elisabeth
Terhart, Maria
Reuter, Uwe
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s10194-023-01552-x
- URN
-
urn:nbn:de:101:1-2023042621303146059413
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 14.08.2025, 10:53 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Raffaelli, Bianca
- Fitzek, Mira
- Overeem, Lucas H.
- Storch, Elisabeth
- Terhart, Maria
- Reuter, Uwe
- SpringerLink (Online service)
Other Objects (12)
Monoclonal antibodies against CGRP (R): non-responders and switchers: real world data from an austrian case series
What to do with non-responders to CGRP(r) monoclonal antibodies: switch to another or move to gepants?
Galcanezumab effects on incidence of headache after occurrence of triggers, premonitory symptoms, and aura in responders, non-responders, super-responders, and super non-responders
Inflammatory complications of CGRP monoclonal antibodies: a case series
Third COVID-19 vaccine dose boosts neutralizing antibodies in poor responders
Effectiveness of CGRP (-Receptor) monoclonal antibodies after treatment re-initiation
CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients
Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
Brain perfusion in fibromyalgia patients and its differences between responders and poor responders to gabapentin
“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies
Real-World Analysis of Clinical Characteristics, Treatment Patterns, and Patient-Reported Outcomes of Insufficient Responders and Responders to Prescribed Acute Migraine Treatment in China
Cardiovascular and cardiorespiratory effects of high-intensity interval training in body fat responders and non-responders
Monoclonal antibodies against CGRP (R): non-responders and switchers: real world data from an austrian case series
What to do with non-responders to CGRP(r) monoclonal antibodies: switch to another or move to gepants?
Galcanezumab effects on incidence of headache after occurrence of triggers, premonitory symptoms, and aura in responders, non-responders, super-responders, and super non-responders
Inflammatory complications of CGRP monoclonal antibodies: a case series
Third COVID-19 vaccine dose boosts neutralizing antibodies in poor responders
Effectiveness of CGRP (-Receptor) monoclonal antibodies after treatment re-initiation
CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients
Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
Brain perfusion in fibromyalgia patients and its differences between responders and poor responders to gabapentin
“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies
Real-World Analysis of Clinical Characteristics, Treatment Patterns, and Patient-Reported Outcomes of Insufficient Responders and Responders to Prescribed Acute Migraine Treatment in China
Cardiovascular and cardiorespiratory effects of high-intensity interval training in body fat responders and non-responders
Monoclonal antibodies against CGRP (R): non-responders and switchers: real world data from an austrian case series
What to do with non-responders to CGRP(r) monoclonal antibodies: switch to another or move to gepants?
Galcanezumab effects on incidence of headache after occurrence of triggers, premonitory symptoms, and aura in responders, non-responders, super-responders, and super non-responders
Inflammatory complications of CGRP monoclonal antibodies: a case series
Third COVID-19 vaccine dose boosts neutralizing antibodies in poor responders
Effectiveness of CGRP (-Receptor) monoclonal antibodies after treatment re-initiation
CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients
Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
Brain perfusion in fibromyalgia patients and its differences between responders and poor responders to gabapentin
“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies
Real-World Analysis of Clinical Characteristics, Treatment Patterns, and Patient-Reported Outcomes of Insufficient Responders and Responders to Prescribed Acute Migraine Treatment in China